A Phase 3 interventional study of Human albumin in Diuretics Drug Reactions, Heart Failure; With Decompensation and Albumin; Double, sponsored by Democritus University of Thrace. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Democritus University of Thrace · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Heart Failure with a site in Greece — 21 open to participants now, 27 under way, 14 of them phase 3. Heart Failure · Greece.
Among the 105 studies in Heart Failure with a site in Greece, this one is the 53rd largest by planned enrollment of the 84 interventional ones that give a count, is one of 2 that started in 2023, is one of 35 in phase 3, reaches primary completion later than 3 of the 26 other live ones, and was the 84th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →21 of the 105 studies in Heart Failure with a site in Greece are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Greece, United States, Argentina and 29 more countries
Ages 18+
Bayer · Sites in Greece, United States, Argentina and 20 more countries
Ages up to 18
Novo Nordisk A/S · Sites in Greece, United States, Argentina and 24 more countries
Ages 18+
University Hospital of Patras · Sites in Greece
Ages 18+
Bayer · Sites in Greece, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 36 · Phase 4 4
First in 1983; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 367 across the 84 interventional studies, 358 across the 20 observational. Of the 65 that completed or were terminated, 32 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 105 have an industry lead sponsor. The 10 most frequent:
Democritus University of Thrace is the lead sponsor of 71 studies on the registry; 9 are open to participants now.
Democritus University of Thrace has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Failure with a site in Greece that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 105 studies in Heart Failure with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.
Acute decompensation of chronic heart failure (CHF) warranting hospital admission, defined as diagnosed on the basis of the presence of at least one symptom (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, weight gain, worsening functional class or edema) and one sign (rales, peripheral edema, ascites, increased jugular vein pressure, hepatomegaly, third heart sound gallop or pulmonary vascular congestion on chest radiography) of heart failure plus laboratory or imaging evidence of hepatic dysfunction at randomization
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
There is no pre-specified inclusion criterion with respect to
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous slow IV infusion of Human Albumin plus IV Furosemide
Drug: Human albumin
Continuous slow IV infusion of Furosemide
Drug: Human albumin
Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
Assessment of symptoms
Patient's global assessment of symptoms, measured with the use of a visual-analogue scale (VAS) and quantified as the area under the curve (AUC) of serial assessments.
Time frame: From baseline to 72 hours.
Change in the serum creatinine level
Change in the serum creatinine level
Time frame: From baseline to 72 hours.
Patient-reported dyspnea
Patient-reported dyspnea (as assessed with the use of a VAS and quantified as the AUC of serial assessments)
Time frame: From baseline to 72 hours.
Changes in body weight
Changes in body weight
Time frame: From baseline to 72 hours.
Length of stay
Length of stay
Time frame: From baseline to discharge.
The composite of death, rehospitalization, escalation in treatment or an emergency room visit within 180 days.
The composite of death, rehospitalization, escalation in treatment or an emergency room visit within 180 days.
Time frame: From baseline to 180 days from discharge.
Net fluid loss
Net fluid loss
Time frame: From baseline to 72 hours
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 34 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human
Democritus University of Thrace